HCC

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

Retrieved on: 
Monday, March 28, 2022
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Treatment, TASE, Company, Drug development, Inflammation, Cancer, Colon, Therapy, Fatty liver disease, Drug, Institute of Liver and Biliary Sciences, Marketing, Risk, Forward-looking statement, NYSE, Prostate, Liver, SEC, Erectile dysfunction, CANF, Hepatocellular carcinoma, Dermatology, Food, NASH, Industry, Technology, U.S. Securities and Exchange Commission, Liver cancer, COVID-19, Writing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Melanoma, HCC, Patient, Pharmaceutical industry, Psoriasis

The summit takes place April 6-7, 2022 and will focus on transformational new dermatological therapeutics being brought to market through collaboration.

Key Points: 
  • The summit takes place April 6-7, 2022 and will focus on transformational new dermatological therapeutics being brought to market through collaboration.
  • Piclidenoson has been out-licensed for the indication of psoriasis to distribution partners in Canada, China, Korea, and numerous countries in Eastern and Western Europe.
  • Can-Fite has received approximately $20 million in upfront and milestone payments from out-licensing deals of its drug pipeline to date.
  • Distribution rights for Piclidenoson are still available for some of the largest markets in Europe and we believe Dermatology Drug Development Summit, with its focus on collaboration, is a great venue to explore additional out-licensing partnerships.

Can-Fite Reports 2021 Financial Results & Provides Clinical Update

Retrieved on: 
Thursday, March 24, 2022
Oncology, Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Mission statement, NYSE, Research, SEC, CANF, Hepatocellular carcinoma, Psoriasis, Primary sclerosing cholangitis, Fibrosis, Annual report, Insurance, Security (finance), TASE, Cannabinoid, U.S. FDA, Balance sheet, Institute of Liver and Biliary Sciences, Petah Tikva, Achievement, NASH, Industry, Liver cancer, U.S. Securities and Exchange Commission, Cirrhosis, Corporation, Phase, Patent, Rheumatoid arthritis, HCC, FDA, Patient, Company, Exercise, Autoimmune hepatitis, Incidence, The Annual Report, CBD, Public relations, COVID-19, NAFLD, Growth, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Socialist Union of Central-Eastern Europe, Cancer

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2021.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2021.
  • Corporate and Clinical Development Highlights Include:
    Fortified Balance Sheet On December 31, 2021, Can-Fite had $18.9 million in cash, cash equivalents, and short-term deposits.
  • Financial income, net for the year ended December 31, 2021 was $0.23 million compared to financial expense, net of $0.3 million for the same period in 2020.
  • The Company's consolidated financial results for the twelve months ended December 31, 2021 are presented in accordance with US GAAP Reporting Standards.

Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance

Retrieved on: 
Tuesday, March 22, 2022
Research, Medical Devices, FDA, Clinical Trials, Other Health, Biotechnology, Health, Science, Oncology, Other Science, National Lung Screening Trial, Cancer, Brag, Diagnosis, Medical device, CE marking, LCS, Cade, Technology, Precision medicine, CEO, Software, Lung cancer staging, ISIN, Sensitivity, NLST, NASH, Health, Artificial intelligence, Liver cancer, SME, Lists of diseases, HCC, Solution, Cave rescue, Cirrhosis, FDA, Lung cancer, Patient, DS, Data science, Prognosis, Medical imaging

Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early detection and characterization of lung cancer nodules and improve clinical management of patients.

Key Points: 
  • Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early detection and characterization of lung cancer nodules and improve clinical management of patients.
  • With this breakthrough innovation, Medians iBiopsy LCS SaMD brings a unique AI-powered solution for clinicians to fight lung cancer, the deadliest cancer worldwide.
  • Results released today show unrivalled performance for Medians end-to-end detection/diagnosis approach for lung cancer screening.
  • These results pave the way for a disruptive approach in lung cancer screening management, Fredrik Brag, CEO and founder of Median Technologies said.

Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform

Retrieved on: 
Thursday, March 24, 2022
Drug development, Therapy, NASDAQ, DNA, KIP, Inovio Pharmaceuticals, Forward-looking statement, Immunotherapy, Death, Serie A2 Basket, Board, RECIST, Survival, Research, Neoplasm, Incidence, Cancer, PD-1, Immune system, Technology, Liver cancer, Diane Fleri, Lists of diseases, HCC, GT, Patient, Pembrolizumab, Pharmaceutical industry, Medical imaging, Geneo Grissom, Director

PLYMOUTH MEETING, Pa., March 24, 2022 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced today that it has secured $17 million in Series A2 financing. The financing was led by Flerie Invest with participation from all existing Series A investors including Santé Ventures, Korea Investment Partners (KIP) – Global Bio Fund, and INOVIO Pharmaceuticals, Inc. (NASDAQ: INO). In conjunction with the financing, Dr. Ted Fjällman, Partner, Flerie Invest joined Geneos' Board of Directors.

Key Points: 
  • "Geneos' personalized immunotherapy shows compelling clinical data in liver cancer patients and the approach is well differentiated from the competition," commented Dr Fjllman.
  • GT-30 evaluates Geneos' personalized cancer vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer.
  • For more information about the company and its leadership team, visit www.geneostx.com
    At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment.
  • Geneos Therapeutics' proprietary GT-EPIC Neoantigen-Targeting Platform is based on the design and delivery of highly optimized synthetic DNA plasmids and their combinations for cancer immunotherapy.

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

Retrieved on: 
Wednesday, March 23, 2022
BCMA, CGMP, BLA, Therapy, PC, HK, Hepatocellular carcinoma, NMPA, Research Triangle Park, CCL21, Technology, NDA, Oncology, GMP, Pancreatic cancer, Hong Kong Stock Exchange, Marketing, CMC, Korea, View, Annual general meeting, LADAR, CD19, PRIME, EMA, South Korea, CDE, IIT, American Society of Hematology, Phase, Cancer, Plasmid, RTP, Multimedia, Board, NHL, CRS, Extensor hallucis longus muscle, Multiple myeloma, KOSDAQ, Society, European Society of Gene and Cell Therapy, HCC, ESMO, FDA, Patient, Company, IND, CAR, Phase II, Neoplasm, Safety, Orphan drug, ASH, Artificiality, Pharmaceutical industry, Vaccine, Animal

In North America, CARsgen has initiated the Phase 1b trial of CT041-ST-02 and has treated the first subject in July 2021.

Key Points: 
  • In North America, CARsgen has initiated the Phase 1b trial of CT041-ST-02 and has treated the first subject in July 2021.
  • CARsgen strives to explore and develop innovative technology platforms to address these challenges to generate better cell therapy products to global cancer patients.
  • The main focus includes:
    Increasing efficacy against solid tumors: developing innovative technologies, such as CycloCAR technology, to enhance efficacies of CAR T-cell against solid tumors.
  • Improving target availability: exploring innovative technologies that can potentially enhance drug target availability and specificity of CAR T-cell therapy.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

Retrieved on: 
Thursday, March 17, 2022
LOXL2, Annual report, Code, NASH, Form 8-K, Idiopathic pulmonary fibrosis, Multiple sclerosis, Patent, GLOBE, Patient, Nasdaq, Substance dependence, Failure, Private Securities Litigation Reform Act, Tokyo Stock Exchange, Capsule, HCC, FDA, Fatty liver disease, Fibrosis, Risk, Glioblastoma, Ascites, Asterixis, DCM, Tablet, Cirrhosis, Security (finance), NASDAQ, Hypertriglyceridemia, Amyotrophic lateral sclerosis, CCR2, Form 10-K, MCP-1, NAFLD, Korean Intellectual Property Office, Inflammation, Fast Track, PDE, Intellectual property, ALS, Splenomegaly, IPF, Gene, U.S. Securities and Exchange Commission, Hepatocellular carcinoma, Neurodegeneration, MS, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanMay 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanMay 2035.
  • The allowed claims cover MN-001 (tipelukast) and MN-002 for the treatment of a patient with advanced NASH wherein the treatment is for reducing hepatic fibrosis in a patient suffering from advanced NASH.
  • In addition, the allowed claims cover MN-001 (tipelukast) and MN-002 for reducing hepatic scarring in a patient with advanced NASH.
  • The U.S. Patent andTrademark Officepreviously granted a patent which covers MN-001 and MN-002 for advanced NASH with fibrosis and a similar patent was granted in Japan.

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer

Retrieved on: 
Wednesday, March 16, 2022
RGCB, SEC, Time, Autophagy, Hepatocellular carcinoma, Technology, Liver, Liver cancer, Patient, Apoptosis, Partnership, Hep G2, BioMed Central, HCC, Lupus, Cardiovascular disease, Sorafenib, National Data Sharing and Accessibility Policy – Government of India, Regulation, Forward-looking statement, Food and Drug Administration Amendments Act of 2007, OTCQB, Orphan drug, Neoplasm, Patent, Ageing, Rajiv Gandhi Centre for Biotechnology, Cell, Oklahoma Medical Research Foundation, Food, Scientific Reports, Cancer, Incidence, Research, Biomedical Research, Death, Securities Exchange Act of 1934, Drug Quality and Security Act, Securities Act of 1933, Mouse, OMRF, Frontiers, Pharmaceutical industry, Dietary supplement, Biotechnology

NEW YORK, March 16, 2022 /PRNewswire/ --Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ --Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.
  • Denis Corin, Q BioMed CEO, said, "Having successfully completed a very challenging synthesis program, we are now finalizing manufacturing for tox studies.
  • Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.
  • Q BioMed has the exclusive license to the technology through an agreement with RGCB and the Oklahoma Medical Research Foundation.

Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK™ Engager Multispecific Antibodies at 2022 AACR Annual Meeting

Retrieved on: 
Wednesday, March 16, 2022
Association, Cornerstone, Therapy, American Association for Cancer Research, Multiple myeloma, Abstract (summary), Technology, University, GMP, GLOBE, Hebrew University of Jerusalem, Patient, Partnership, AACR, Ink, GPC3, NK, HCC, Eleazar Sukenik, American Association, Glioblastoma, Lymphatic system, Annual general meeting, Neoplasm, Cellectis, Cell, Research, Cancer, CD38, CEO, University of California, San Francisco, UCSF, INSERM, Hepatocellular carcinoma, Laboratory, Vaccine, NCR1

Cytovia is the first immune-oncology company to present data combining its own iPSC-derived NK cells and NK engager antibodies for the treatment of solid tumors.

Key Points: 
  • Cytovia is the first immune-oncology company to present data combining its own iPSC-derived NK cells and NK engager antibodies for the treatment of solid tumors.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms.
  • Cytovia has recently formed CytoLynx Therapeutics, a partnership focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

RAAPID Provides Critical Risk Adjustment Capabilities Nationwide

Retrieved on: 
Tuesday, March 15, 2022
Knowledge, Insurance, Risk, Coding, Technology, GLOBE, Health care, Patient, Natural language, Workforce, RAF, Disease, ROI, HCC, Organization, Google Knowledge Graph, Pedigree, NLP, Physician, Knowledge Organization (journal), Trust, Natural language processing, Health insurance, Online shopping, Medical device

LOUISVILLE, Ky., March 15, 2022 (GLOBE NEWSWIRE) -- RAAPID, the world's first personalized AI assistant for risk capture, is providing healthcare providers and facilitators across the United States with access to the most powerful risk adjustment platform on the market.

Key Points: 
  • LOUISVILLE, Ky., March 15, 2022 (GLOBE NEWSWIRE) -- RAAPID, the world's first personalized AI assistant for risk capture, is providing healthcare providers and facilitators across the United States with access to the most powerful risk adjustment platform on the market.
  • For healthcare organizations, managing risk adjustment is crucial as it directly impacts their return on investment (ROI).
  • Complete with integrated codebooks and comprehensive analytics and reporting, RAAPID offers the most efficient risk adjustment workflow automation capabilities available today.
  • For more information about how RAAPID is quickly transforming the risk adjustment landscape, please visit https://www.raapid.ai/ .

Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, March 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Research, Liver cancer, Risk, Tablet, DTC, VEGFR, Adrenal insufficiency, EXEL, OS, Union, Proteinuria, Embolism, New Drug Application, Takeda Pharmaceutical Company, Nephrotic syndrome, History, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Melena, ONJ, Hoffmann-La Roche, AST, ALT, Hypertension, Death, Nivolumab, Pulmonary embolism, Fistula, Bleeding, Recurrence, Sepsis, Patient, Perforation, RCC, Nasdaq, Sorafenib, Abscess, Fatal, Avascular necrosis, Hormone replacement therapy, Food, Cancer, Ipsen, Progression-free survival, ClinicalTrials.gov, Hematemesis, Drug discovery, Genentech, HCC, FDA, Adult, Medical Affairs Bureau, ULN, Grade 3, Venous thrombosis, Incidence, Hemoptysis, Post-vaccination embolic and thrombotic events, Pharmaceutical industry, Jaw, Exelixis, COSMIC-312, HCC, CABOMETYX, COSMIC-312, HCC, CABOMETYX

COSMIC-312 is a global, multicenter, randomized, controlled phase 3 trial that enrolled 837 patients at 281 study centers globally.

Key Points: 
  • COSMIC-312 is a global, multicenter, randomized, controlled phase 3 trial that enrolled 837 patients at 281 study centers globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX is not indicated as a treatment for previously untreated advanced HCC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.